Paper39006295
Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy.
Hong Y and 4 others. Am J Transl Res, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy. Papers, record 39006295. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39006295
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical implications of serum miR-34a in breast cancer and its predictive value for the efficacy of neoadjuvant chemotherapy.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33971623 | MiR-205 suppressed the malignant behaviors of breast cancer cells by targeting CLDN11 via modulation of the epithelial-to-mesenchymal transition. | Aging (Albany NY) | 2021 | https://conductscience.org/library/papers/33971623 | PubMed |
| 2 | 34308576 | MiR-221 Expression Level Correlates with Insulin-Induced Doxorubicin Resistance in MCF-7 Breast Cancer Cells. | Cell J | 2021 | https://conductscience.org/library/papers/34308576 | PubMed |
| 3 | 32336285 | miR-615-3p promotes the epithelial-mesenchymal transition and metastasis of breast cancer by targeting PICK1/TGFBRI axis. | J Exp Clin Cancer Res | 2020 | https://conductscience.org/library/papers/32336285 | PubMed |
| 4 | 17888029 | Association of microRNA-34a overexpression with proliferation is cell type-dependent. | Cancer Sci | 2007 | https://conductscience.org/library/papers/17888029 | PubMed |
| 5 | 27062696 | Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer. | Cancer Biomark | 2016 | https://conductscience.org/library/papers/27062696 | PubMed |
| 6 | 30860027 | Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. | Elife | 2019 | https://conductscience.org/library/papers/30860027 | PubMed |
| 7 | 34323695 | The synergy between miR-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant breast cancer cells. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/34323695 | PubMed |
| 8 | 36831192 | Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis. | Cells | 2023 | https://conductscience.org/library/papers/36831192 | PubMed |
| 9 | 34315439 | Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial. | BMC Cancer | 2021 | https://conductscience.org/library/papers/34315439 | PubMed |
| 10 | 23001043 | MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. | Oncogene | 2013 | https://conductscience.org/library/papers/23001043 | PubMed |
| 11 | 29473328 | LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer. | Cancer Med | 2018 | https://conductscience.org/library/papers/29473328 | PubMed |
| 12 | 34281852 | Phase II Study of Nab-paclitaxel Plus Cyclophosphamide Plus Trastuzumab Neoadjuvant Chemotherapy in Early HER-2-positive Breast Cancer. | Anticancer Res | 2021 | https://conductscience.org/library/papers/34281852 | PubMed |
| 13 | 31797701 | A Novel lncRNA HOXC-AS3 Acts as a miR-3922-5p Sponge to Promote Breast Cancer Metastasis. | Cancer Invest | 2020 | https://conductscience.org/library/papers/31797701 | PubMed |
| 14 | 32144736 | miR-485-5p inhibits the progression of breast cancer cells by negatively regulating MUC1. | Breast Cancer | 2020 | https://conductscience.org/library/papers/32144736 | PubMed |
| 15 | 32186770 | MicroRNA‑34a expression affects breast cancer invasion in vitro and patient survival via downregulation of E2F1 and E2F3 expression. | Oncol Rep | 2020 | https://conductscience.org/library/papers/32186770 | PubMed |
| 16 | 25078559 | Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. | J Cell Physiol | 2015 | https://conductscience.org/library/papers/25078559 | PubMed |
| 17 | 32102529 | Dynamic Changes of Circulating Mir-155 Expression and the Potential Application as a Non-Invasive Biomarker in Breast Cancer. | Asian Pac J Cancer Prev | 2020 | https://conductscience.org/library/papers/32102529 | PubMed |
| 18 | 34307126 | Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study. | Front Oncol | 2021 | https://conductscience.org/library/papers/34307126 | PubMed |
| 19 | 34306209 | MicroRNA-301a-3p promotes triple-negative breast cancer progression through downregulating MEOX2. | Exp Ther Med | 2021 | https://conductscience.org/library/papers/34306209 | PubMed |
| 20 | 35246810 | The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. | Ann Surg Oncol | 2022 | https://conductscience.org/library/papers/35246810 | PubMed |
Cited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42319671 | The role of circulating MiR-34a-5p and MiR-let7a-5p as a diagnostic tumor markers in breast cancer a cross-sectional analysis. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42319671 | PubMed |
| 41749302 | Abnormal expression of miR-22-5p in breast cancer patients and its correlation with 18 F-FDG PET/CT features and serum-related tumor markers. | World J Surg Oncol | 2026 | https://conductscience.org/library/papers/41749302 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MIR34A | 407040 | PubTator's text mining | https://conductscience.org/library/genes/407040 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39006295
GET https://conductscience.org/api/papers/v1/39006295/references?page=2